Tissue plasminogen activator therapy for the eye

British Journal of Ophthalmology

Volumn 89, Issue 11, 2005, Pages 1390-1391

  Tripathi, Ramesh C ^a,b   Tripathi, B J ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Department of Ophthalmology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANTIBIOTIC AGENT;

BLOOD CLOT LYSIS; CATARACT; CATARACT EXTRACTION; CONGENITAL CATARACT; EDITORIAL; FIBRIN FORMATION; FIBRINOLYSIS; HUMAN; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL;

EXUDATES AND TRANSUDATES; FIBRINOLYTIC AGENTS; HUMANS; OPHTHALMOLOGIC SURGICAL PROCEDURES; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; RECOMBINANT PROTEINS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 27344440316     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2005.074401     Document Type: Editorial

References (42)

1. Tripathi RC, Tripathi BJ, Bornstein S, et al. Use of tissue plasminogen activator for rapid dissolution of fibrin and blood clots in the eye after surgery for glaucoma and cataract in humans. Drug Dev Res 1992;27:147-59.
2. Park JK, Tripathi RC, Tripathi BJ, et al. Tissue plasminogen activator in the trabecular endothelium. Invest Ophthalmol Vis Sci 1987;28:1341-5.
3. Geanon JD, Tripathi BJ, Tripathi RC, et al. Tissue plasminogen activator in avascular tissues of the eye: a quantitative study of its activity in the cornea, lens, and aqueous and vitreous humors of dog, calf, and monkey. Exp Eye Res 1987;44:55-63.
4. Tripathi RC, Park JK, Tripathi BJ, et al. Tissue plasminogen activator in human aqueous humor and its possible therapeutic significance. Am J Ophthalmol 1988;106:719-22.
5. Kwaan HC, Samama MM, Nguyen G. Fibrinolytic systems. In: Kwaan HC, Samama MM, eds. Clinical thrombosis. Boca Raton: CRC Press, 1989:23-31.
6. Weitz JI, Stewart PJ, Fredenburgh JC. Mechanism of action of plasminogen activators. Thromb Haemost 1999;82:974-82.
7. Collen D, Lijen HR. Tissue-type plasminogen activator: a historical perspective and personal account. J Thromb Haemost 2004;2:541-6.
8. Forrester JV, Williamson J. Lytic therapy in vitreous haemorrhage. Trans Ophthalmol Soc UK 1974;94:583-6.
9. Bramsen T. The effect of urokinase on central corneal thickness and vitreous haemorrarige. Acta Ophthalmol 1978;56:1006-12.
10. Textorius O, Stenkula S. Toxic ocular effects of two fibrinolytic drugs: an experimental electroretinographic study on albino rabbits. Arch Ophthalmol 1983;61:322-31.
11. Mindel JS. Special topics. Part 2: Drugs affecting blood. In: Duane TD, ed. Biomedical foundations of ophthalmology Philadelphia, Harper and Row, 1991;41:1-26.
12. Tripathi RC, Tripathi BJ, Park JK, et al. Intracameral tissue plasminogen activator for resolution of fibrin clots after glaucoma filtering procedures. Am J Ophthalmol 1991;111:247-28.
13. Snyder RW, Sherman MD, Allinson RW. Intracameral tissue plasminogen activator for treatment of excessive fibrin response after penetrating keratoplasty. Am J Ophthalmol 1990;109:483-4.
14. Williams GA, Lambrou FH, Jaffe GJ, et al. Treatment of postvitrectomy fibrin formation with intraocular tissue plasminogen activator. Arch Ophthalmol 1988;106:1055-8.
15. Jaffe GJ, Lewis H, Han DP, et al. Treatment of postvitrectomy fibrin pupillary block with tissue plasminogen activator. Am J Ophthalmol 1989;108:170-5.
16. Jaffe GJ, Abrams GW, Williams GA, et al. Tissue plasminogen activator for postvitrectomy fibrin formation. Ophthalmology 1990;97:184-9.
17. Dabbs CK, Aaberg TM, Aguilar HE, et al. Complications of tissue plasminogen activator therapy after vitrectomy for diabetes. Am J Ophthalmol 1990;110:354-60.
18. Ortiz JR, Walker SD, McManus PE, et al. Filtering bleb thrombolysis with tissue plasminogen activator. Am J Ophthalmol 1988;106:624-65.
19. Baker ND, Lehman DM, Weber PA, et al. Tissue plasminogen activator treatment of failing glaucoma filtering surgery. ARVO Abstract. Invest Ophthalmol Vis Sci 1991;32(suppl 4):1122.
20. Smith MF, Doyle JW. Use of tissue plasminogen activator to revive blebs following intraocular surgery. Arch Ophthalmol 2001;119:809-12.
21. Jameson NA, Good, WV, Hoyt CS. Inflammation after cataract surgery in children. Ophthalmic Surg Lasers 1992;23:99-102.
22. Fallaha N, Lambert SR. Pediatric cataracts. Ophthalmol Clin N Am 2001;14:479-92.
23. Klais CM, Hattenbach LO, Steinkamp GW, et al. Intraocular recombinant tissue-plasminogen activator fibrinolysis of fibrin formation after cataract surgery in children. J Cataract Refract Surg 1999;25:357-62.
24. Mehta JS, Adams GGW. Recombinant tissue plasminogen activator following paediatric cataract surgery. Br J Ophthalmol 2000;84:983-6.
25. Rijken DC, Otter M, Kuiper J, et al. Receptor-mediated endocytosis of tissue-type plasminogen activator (t-PA) by liver cells. Thromb Res Suppl 1990;10:63-71.
26. Wedrich A, Menapace R, Muhlbauer-Ries E. The use of recombinant tissue plasminogen activator for intracameral fibrinolysis following cataract surgery. Int Ophthalmol, 1994-95, 18:277-80.
27. Wedrich A, Menapace R, Reis E, et al. Intracameral tissue plasminogen activator to treat severe fibrinous effusion after cataract surgery. J Cataract Refract Surg 1997;23:873-7.
28. Georgiadis N, Bobiridis K, Halvatzis N, et al. Low-dose tissue plasminogen activator in the management of anterior chamber fibrin formation. J Cataract Refract Surg 2003;29:729-32.
29. Erol N, Ozer A, Topbas S, et al. Treatment of intracameral fibrinous membranes with tissue plasminogen activator. Ophthalmic Surg Lasers Imaging 2003;34:451-6.
30. Williams DF, Bennett SR, Abrams GW, et al. Low-dose intraocular tissue plasminogen activator for treatment of postvitrectomy fibrin formation. Am J Ophthalmol 1990;109:606-7.
31. Abrams GW, Murray TG, Boldt HC, et al. Tissue plasminogen activator (t-PA): determination of clinical limits of efficacy for intracameral delivery. ARVO abstract. Invest Ophthalmol Vis Sci 1991;32(suppl 4):1226.
32. Starck T, Hopp L, Held KS, et al. Low-dose intraocular tissue plasminogen activator treatment for traumatic total hyphema, postcataract, and penetrating keratoplasty fibrinous membranes. J Cataract Refract Surg 1995;21:219-24.
33. Lundy DC, Sidoti P, Winarko T, et al. Intracameral tissue plasminogen activator after glaucoma surgery. Indications, effectiveness, and complications. Ophthalmology 1996;103:274-82.
34. Heiligenhaus A, Steinmetz B, Lapuente R, et al. Recombinant tissue plasminogen activator in cases with fibrin formation after cataract surgery: a prospective randomised multicentre study. Br J Ophthalmol 1998;82:810-15.
35. Kim MH, Koo TH, Sah WJ, et al. Treatment of total hyphema with relatively low-dose tissue plasminogen activator. Ophthalmic Surg Lasers 1998;29:762-6.
36. Lambrou FH, Synder RW, Williams GA. Use of tissue plasminogen activator in experimental hypema. Arch Ophthalmol 1987;105:995-7.
37. Wollensak G, Meyer JH, Loffler KU, et al. Band-like keratopathy after treatment of postoperative fibrin reaction with tissue plasminogen activator. Klin Monatsbl Augenheilkd 1996;209:43-6.
38. Chen SN, Yang TC, Ho CL, et al. Retinal toxicity of intravitreal tissue plasminogen activator: case report and literature review. Ophthalmology 2003;110:704-8.
39. Lim JI, Fiscella R, Tessler H, et al. Intraocular penetration of topical tissue plasminogen activator. Arch Ophthalmol 1991;109:714-17.
40. Lim JI, Maguire AM, John G, et al. Intraocular tissue plasminogen activator concentrations after subconjunctival delivery. Ophthalmology 1993;100:373-6.
41. Cellini M, Baldi A, Possati GL. Topical treatment of postvitrectomy fibrin formation with tissue plasminogen activator. Int Ophthalmol 1994-95;18:351-3.
42. Zwaan J, Latimer WB. Topical tissue plasminogen activator appears ineffective for the clearance of intraocular fibrin. Ophthalmic Surg Lasers 1998;29:476-83.